BioSpace News Archive

EB-101 treatment of large, chronic wounds is associated with durable healing and pain relief in patients with RDEB Literature review of 65 studies confirms and expands understanding of substantial disease burden of RDEB with considerable clinical, economic and humanistic impact on patients and their families NEW YORK and CLEVELAND, July 10, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two post

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or “the Company”) today provided an update on progress with its SARS-CoV-2 (COVID-19) vaccine candidate and announced the termination of its clinical development program with AG013 for the treatment of severe oral mucositis in cancer patients. While working with Aragen Bioscience, a leading contract research

Ocumension Therapeutics (“Ocumension”), a China -based ophthalmic pharmaceutical platform company, has today launched its Initial Public Offering (IPO) of the company’s stock on The Stock Exchange of Hong Kong (HKEX). Ocumension plans to offer 105,930,000 shares priced at HK$14.66 each and will trade under the stock code “1477.HK”. Mor

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it plans to release its financial results for the second quarter of 2020 after market close on Thursday, August 13, 2020. A conference call hosted by Michael Guerriere, President and Chief Executive Officer and David Bacon, Senior Vice President and Chief Financial Officer, will be held on August 14, 2020, at 11:30 a.m. (ET) to discuss the results. To participa

Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced the conversion of accrued compensation due to the Company’s Chief Executive Officer, Chief Innovation Officer and two senior advisors to equity units with the same terms as the Company’s

Sexton Biotechnologies and CCMI Galway collaborative effort leads to approval by EU regulatory authorities for the use of nLiven PR in the expansion of an allogeneic MSC therapeutic product to address corneal transplant rejection [10-July-2020] INDIANAPOLIS and GALWAY, Ireland , July 10, 2020 /PRNewswire/ -- The Centre for Cell Manufacturing Ireland (CCMI) at the Nat

Tyme Technologies, Inc. (NASDAQ: TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that TYME will hold its 2020 Annual Meeting of Stockholders in a virtual-only format, as a result of public health concerns relating to the coronavirus (COVID-19) and to protect the health and well-being of its share

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced the appointment of Sara Bonstein to its Board of Directors. Ms. Bonstein fills the vacancy created from Dorothy Coleman’s resignation from the Board of Directors. Ms. Co

The V Foundation Wine Celebration is going virtual on August 8, 2020 by presenting “MOMENTUM 2.0,” an immersive, digital auction experience supporting the V Foundation’s fight to achieve Victory Over Cancer®. Each year, as part of the annual event, the V Foundation Wine Celebration hosts the Answer for Cancer research symposium, where world-class

Director General of the International Vaccine Institute (IVI) will speak to vaccine development and the role of contact tracing in combating coronavirus BOCA RATON, Fla.--( BUSINESS WIRE )-- Modernizing Medicine® , a leading healthcare technology company, is hosting a new installment in its thought leadership webinar series . The session, “World War C: Contact Tracing and the Hunt for a Vaccine,” will take place virtually on Tuesday, July 14 at 7 P